Scale-up of antiretroviral therapy in low- and middle-income countries has been achieved by using a public health approach that involved national standard regimens and clinical monitoring in settings where laboratory infrastructure was not available. This strategy potentially allows for long periods of unrecognized viral failure, during which drug-resistant virus can be transmitted and this could compromise the long-term effectiveness of currently available first-line regimens. In response to this concern, the World Health Organization recommends population-based surveys to detect whether the prevalence of resistance in ART-naive people is reaching alerting levels. Whereas adherence counseling has to be an integral component of any treatment program, it is still unclear which threshold of transmitted drug resistance (TDR) should trigger additional targeted public health actions and which action is the most cost-effective. Mathematical models can contribute to answer these questions. In order to estimate the potential long-term impact of TDR on mortality in people on ART we used the Synthesis transmission model. TDR is predicted to have potentially significant impact on future HIV mortality. It is critical to remain vigilant over transmission of drug-resistant HIV.
Journal of Infectious Diseases, 2013, Vol 207 Suppl 2
Anti-Retroviral Agents; Cost-Benefit Analysis; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Geography; HIV; HIV Infections; Health Resources; Humans; Models, Theoretical; Mutation; Population Surveillance; Poverty; Prevalence; Public Health; Time Factors; Treatment Outcome; Viral Load; World Health Organization; Journal Article; Research Support, Non-U.S. Gov't